Nrx pharmaceuticals, inc.NRXP.US Overview

US StockHealthcare

(No presentation for NRXP)

Overview AI Analysis AI Earnings Summary Financials Financial Forecast Stock Sentimental Institutions TradingView Chart

NRXP Overall Performance

NRXP AI Analysis & Strategy

NRXP Recent Performance

0.53%

Nrx pharmaceuticals, inc.

1.30%

Avg of Sector

0.61%

S&P500

NRXP PowerScanner

NRXP Key Information

NRXP Valuation Metrics

NRXP Earnings Table

NRXP Profile

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.